SCHEMBL1507053

SCHEMBL1507053

COC(=O)c1ccc(C(=O)C2=C(C)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 4/20 0.52
PTPRC P08575 1/20 0.52
PTPRF P10586 1/20 0.52
PTPN1 P18031 1/20 0.52
CDC25A P30304 3/20 0.51
FGFR1 P11362 1/20 0.50
SRC P12931 1/20 0.50
FGFR2 P21802 1/20 0.50
FGFR4 P22455 1/20 0.50
FGFR3 P22607 1/20 0.50
TSHR P16473 1/20 0.49
TDP1 Q9NUW8 1/20 0.47
CYP19A1 P11511 1/20 0.47
IDO1 P14902 2/20 0.46
TDO2 P48775 1/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12834566 0.85 MAPT (0.53) CDC25BCDC25AFGFR1SRCFGFR2
SCHEMBL12761941 0.84 ALDH1A1 (0.51) CDC25BCDC25ATDP1POLBSMN1; SMN2
SCHEMBL7098579 0.84 ALDH1A1 (0.62) CDC25BCDC25AFGFR1FGFR2FGFR4
SCHEMBL12834559 0.83 LMNA (0.49) CDC25BCDC25ATDP1POLBSMN1; SMN2
SCHEMBL12834560 0.83 KMT2A (0.59) CDC25BPTPRCCDC25AFGFR1FGFR2
SCHEMBL12834569 0.81 ALDH1A1 (0.47) CDC25BCDC25ATDP1POLBSMN1; SMN2
SCHEMBL12834576 0.81 ALDH1A1 (0.58) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL12834565 0.81 KMT2A (0.51) CDC25BCDC25ATDP1IDO1TDO2
SCHEMBL12969793 0.79 MEN1 (0.55) CDC25BPTPRCFGFR1FGFR2FGFR4
SCHEMBL12834571 0.79 SRD5A2 (0.47) CDC25BCDC25ATDP1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257515-B1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2017-05-17 EP disclosed
US-9090549-B2 1,4-naphthoquinones derivatives and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2015-07-28 US disclosed
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-10 US disclosed
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-10 US disclosed
EP-2257515-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF Centre National de la Recherche Scientifique (FR) 2010-12-08 EP disclosed
WO-2009118327-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF NQO1, NDUFV2, RECQL CDC25B 576/4885PTPRC 2021/4885PTPRF 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.